Fig. 2
From: Prenatal muscle development in a mouse model for the secondary dystroglycanopathies
Immunolabelling of α- and β-dystroglycan, dystrophin and perlecan. a Transverse sections through the TA and EDL at E15.5 and P0 immunolabelled for α- (A-D) and β-dystroglycan (E-H), dystrophin (Mandys1, I-L) and perlecan (M-P). α-dystroglycan (IIH6) showed a clear delineation of the basement membrane around clusters of primary and secondary myotubes at E15.5 (A) and individual muscle fibres at P0 (C), although some clusters are still evident. There was an almost total absence of IIH6 in the FKRPKD at both time points (B,D). Residual staining of the neuromuscular junction in the FKRPKD at P0 is shown in D as an inserted image. β-dystroglycan, dystrophin and perlecan immunolabelling were not markedly different between FKRPKD and wild type at either time point (E-P)